MiR-182-5p and Its Target HOXA9 in Non-small Cell Lung Cancer: a Clinical and In-silico Exploration with the Combination of RT-qPCR, MiRNA-seq and MiRNA-chip

Overview

Journal BMC Med Genomics

Publisher Biomed Central

Specialty Genetics

Date 2020 Jan 8

PMID 31906958

Citations 17

Authors

Li Gao

Shi-Bai Yan

Jie Yang

Jin-Liang Kong

Ke Shi

Fu-Chao Ma

Lin-Zhen Huang

Jie Luo

Shu-Ya Yin

Rong-Quan He

Xiao-Hua Hu

Gang Chen

Affiliations

Soon will be listed here.

Abstract

Background: MiR-182-5p, a cancer-related microRNA (miRNA), modulates tumorigenesis and patient outcomes in various human malignances. This study interroted the clinicopathological significance and molecular mechanisms of miR-182-5p in non-small cell lung cancer (NSCLC).

Methods: The clinical significance of miR-182-5p in NSCLC subtypes was determined based on an analysis of 124 samples (lung adenocarcinomas [LUADs], n = 101; lung squamous cell carcinomas [LUSCs], n = 23) obtained from NSCLC patients and paired noncancer tissues and an analysis of data obtained from public miRNA-seq database, miRNA-chip database, and the scientific literature. The NSCLC samples (n = 124) were analyzed using the real-time quantitative polymerase chain reaction (RT-qPCR). Potential targets of miR-182-5p were identified using lists generated by miRWalk v.2.0, a comprehensive atlas of predicted and validated targets of miRNA-target interactions. Molecular events of miR-182-5p in NSCLC were unveiled based on a functional analysis of candidate targets. The association of miR-182-5p with one of the candidate target genes, homeobox A9 (HOXA9), was validated using in-house RT-qPCR and dual-luciferase reporter assays.

Results: The results of the in-house RT-qPCR assays analysis of data obtained from public miRNA-seq databases, miRNA-chip databases, and the scientific literature all supported upregulation of the expression level of miR-182-5p level in NSCLC. Moreover, the in-house RT-qPCR data supported the influence of upregulated miR-182-5p on malignant progression of NSCLC. In total, 774 prospective targets of miR-182-5p were identified. These targets were mainly clustered in pathways associated with biological processes, such as axonogenesis, axonal development, and Ras protein signal transduction, as well as pathways involved in axonal guidance, melanogenesis, and longevity regulation, in multiple species. Correlation analysis of the in-house RT-qPCR data and dual-luciferase reporter assays confirmed that HOXA9 was a direct target of miR-182-5p in NSCLC.

Conclusions: The miR-182-5p expression level was upregulated in NSCLC tissues. MiR-182-5p may exert oncogenic influence on NSCLC through regulating target genes such as HOXA9.

Citing Articles

Pan-cancer exploration of oncogenic and clinical impacts revealed that HOXA9 is a diagnostic indicator of tumorigenesis.

Shenoy U, Basavarajappa D, Kabekkodu S, Radhakrishnan R Clin Exp Med. 2024; 24(1):134.

PMID: 38904676 PMC: 11192824. DOI: 10.1007/s10238-024-01389-x.

Identifying the differentially expressed peripheral blood microRNAs in psychiatric disorders: a systematic review and meta-analysis.

Liu X, Dong L, Jiang Z, Song M, Yan P Front Psychiatry. 2024; 15:1390366.

PMID: 38827444 PMC: 11140110. DOI: 10.3389/fpsyt.2024.1390366.

HOXA9 transcription factor is a double-edged sword: from development to cancer progression.

Shenoy U, Adiga D, Alhedyan F, Kabekkodu S, Radhakrishnan R Cancer Metastasis Rev. 2023; 43(2):709-728.

PMID: 38062297 PMC: 11156722. DOI: 10.1007/s10555-023-10159-2.

The miR-183 Cluster: Biogenesis, Functions, and Cell Communication via Exosomes in Cancer.

Li S, Meng W, Guo Z, Liu M, He Y, Li Y Cells. 2023; 12(9).

PMID: 37174715 PMC: 10177187. DOI: 10.3390/cells12091315.

DNA hypermethylation-induced miR-182 silence targets BCL2 and HOXA9 to facilitate the self-renewal of leukemia stem cell, accelerate acute myeloid leukemia progression, and determine the sensitivity of BCL2 inhibitor venetoclax.

Ye S, Xiong F, He X, Yuan Y, Li D, Ye D Theranostics. 2023; 13(1):77-94.

PMID: 36593968 PMC: 9800726. DOI: 10.7150/thno.77404.

References

Lu C, Shan Z, Hong J, Yang L . MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis. Int J Oncol. 2017; 51(1):235-244. DOI: 10.3892/ijo.2017.3999. View

Kobayashi H, Tomari Y . RISC assembly: Coordination between small RNAs and Argonaute proteins. Biochim Biophys Acta. 2015; 1859(1):71-81. DOI: 10.1016/j.bbagrm.2015.08.007. View

Zhao C, Lu F, Chen H, Zhao F, Zhu Z, Zhao X . Clinical significance of circulating miRNA detection in lung cancer. Med Oncol. 2016; 33(5):41. DOI: 10.1007/s12032-016-0757-5. View

Zhou Q, Song Y, Zhang X, Chen G, Zhong D, Yu Z . A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506). BMC Cancer. 2017; 17(1):462. PMC: 5496179. DOI: 10.1186/s12885-017-3451-x. View

Wong P, Hui A, Su J, Yue S, Haibe-Kains B, Gokgoz N . Prognostic microRNAs modulate the RHO adhesion pathway: A potential therapeutic target in undifferentiated pleomorphic sarcomas. Oncotarget. 2015; 6(36):39127-39. PMC: 4770761. DOI: 10.18632/oncotarget.3926. View

Gao L, Li S, Tian Y, Zhu Q, Chen G, Pang Y . Role of downregulated miR-133a-3p expression in bladder cancer: a bioinformatics study. Onco Targets Ther. 2017; 10:3667-3683. PMC: 5530854. DOI: 10.2147/OTT.S137433. View

Zhang B, Zhao R, He Y, Fu X, Fu L, Zhu Z . MicroRNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR. Oncotarget. 2016; 7(5):5702-14. PMC: 4868715. DOI: 10.18632/oncotarget.6790. View

Li C, Liang G, Yao W, Sui J, Shen X, Zhang Y . Identification and functional characterization of microRNAs reveal a potential role in gastric cancer progression. Clin Transl Oncol. 2016; 19(2):162-172. DOI: 10.1007/s12094-016-1516-y. View

Chen W, Gan T, Qin H, Huang S, Yang L, Fang Y . Implication of downregulation and prospective pathway signaling of microRNA-375 in lung squamous cell carcinoma. Pathol Res Pract. 2017; 213(4):364-372. DOI: 10.1016/j.prp.2017.01.007. View

10.

Gu S, Lai Y, Chen H, Liu Y, Zhang Z . miR-155 mediates arsenic trioxide resistance by activating Nrf2 and suppressing apoptosis in lung cancer cells. Sci Rep. 2017; 7(1):12155. PMC: 5610328. DOI: 10.1038/s41598-017-06061-x. View

11.

He R, Li X, Liang L, Xie Y, Luo D, Ma J . The suppressive role of miR-542-5p in NSCLC: the evidence from clinical data and in vivo validation using a chick chorioallantoic membrane model. BMC Cancer. 2017; 17(1):655. PMC: 5606087. DOI: 10.1186/s12885-017-3646-1. View

12.

Yu N, Zhang Q, Liu Q, Yang J, Zhang S . A meta-analysis: microRNAs' prognostic function in patients with nonsmall cell lung cancer. Cancer Med. 2017; 6(9):2098-2105. PMC: 5603832. DOI: 10.1002/cam4.1158. View

13.

Zhu W, Zhou K, Zha Y, Chen D, He J, Ma H . Diagnostic Value of Serum miR-182, miR-183, miR-210, and miR-126 Levels in Patients with Early-Stage Non-Small Cell Lung Cancer. PLoS One. 2016; 11(4):e0153046. PMC: 4836744. DOI: 10.1371/journal.pone.0153046. View

14.

Wang F, Zhong S, Zhang H, Zhang W, Zhang H, Wu X . Prognostic Value of MicroRNA-182 in Cancers: A Meta-Analysis. Dis Markers. 2015; 2015:482146. PMC: 4439499. DOI: 10.1155/2015/482146. View

15.

Chang H, Liu Y, Wang L, Wang J, Zhao Z, Qu J . MiR-182 promotes cell proliferation by suppressing FBXW7 and FBXW11 in non-small cell lung cancer. Am J Transl Res. 2018; 10(4):1131-1142. PMC: 5934572. View

16.

Chen G, Kronenberger P, Umelo I, Teugels E, De Greve J . Quantification of epidermal growth factor receptor T790M mutant transcripts in lung cancer cells by real-time reverse transcriptase-quantitative polymerase chain reaction. Anal Biochem. 2009; 398(2):266-8. DOI: 10.1016/j.ab.2009.11.034. View

17.

Wei Q, Lei R, Hu G . Roles of miR-182 in sensory organ development and cancer. Thorac Cancer. 2015; 6(1):2-9. PMC: 4448460. DOI: 10.1111/1759-7714.12164. View

18.

Bhatlekar S, Fields J, Boman B . HOX genes and their role in the development of human cancers. J Mol Med (Berl). 2014; 92(8):811-23. DOI: 10.1007/s00109-014-1181-y. View

19.

Li C, Yin Y, Liu X, Xi X, Xue W, Qu Y . Non-small cell lung cancer associated microRNA expression signature: integrated bioinformatics analysis, validation and clinical significance. Oncotarget. 2017; 8(15):24564-24578. PMC: 5421870. DOI: 10.18632/oncotarget.15596. View

20.

Wei Y, He R, Wu Y, Gan B, Wu P, Qiu X . Comprehensive investigation of aberrant microRNA profiling in bladder cancer tissues. Tumour Biol. 2016; 37(9):12555-12569. DOI: 10.1007/s13277-016-5121-z. View